Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and multiple ascending dose study of BAY 3283142 in healthy Japanese males
jRCT2071230002Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in chronic kidney disease (CKD) comparing BAY 3283142 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Apr 2023; status: completed.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2071230002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230002.